NOVELTY - Preparing rivaroxaban (I), comprises e.g.: (a) reacting leaving group containing 4-(4-(2-hydroxy-ethylamino)-phenyl)-morpholin-3-one compounds (IV) with leaving group and protecting group containing compounds (V), optionally in presence of base to give protecting group containing 4-(4-(2-hydroxy-ethylamino)-phenyl)-morpholin-3-one compounds (VI); (b) converting (VI) to protecting group containing 4-(4-((S)-3-amino-2-hydroxy-propylamino)-phenyl)-morpholin-3-one compounds (VII); and (c) reacting (VII) with leaving group containing 5-chloro thiophen-2-carboxylic acid compounds (VIII).    USE - The process is useful for preparing (I) (claimed) which is useful for preventing and treating deep vein thrombosis and pulmonary embolism in patients undergoing knee and hip replacement surgery. No biological data given.    ADVANTAGE - The process is an improved, industrially feasible and environmental friendly process.    DETAILED DESCRIPTION - Preparing rivaroxaban of formula (I), comprises: (a) reacting leaving group containing 4-(4-(2-hydroxy-ethylamino)-phenyl)-morpholin-3-one compounds of formula (IV) with leaving group and protecting group containing compound of formula (V), optionally in the presence of a base to give protecting group containing 4-(4-(2-hydroxy-ethylamino)-phenyl)-morpholin-3-one compounds of formula (VI); (b) converting (VI) to protecting group containing 4-(4-((S)-3-amino-2-hydroxy-propylamino)-phenyl)-morpholin-3-one compounds of formula (VII) or its salt which may optionally involve isolation of protecting group containing 4-(4-((R)-3,3,3-triamino-2-hydroxy-propylamino)-phenyl)-morpholin-3-one compounds of formula (VIIA); (c) reacting (VII) or its salt with leaving group containing 5-chloro thiophen-2-carboxylic acid compounds of formula (VIII) in the presence of a base to give protecting group containing 5-chloro-thiophene-2-carboxylic acid((R)-2-hydroxy-3-(4-(3-oxo-morpholin-4-yl)-phenylamino)-propyl)-amide compounds of formula (IX); and (d) deprotecting and cyclizing (IX) to provide (I).    L1 = leaving group; and    G1 = protecting group.    INDEPENDENT CLAIMS are also included for:    (1) process (P2) for preparing (I) comprising: reacting (R)-4-(4-(3-chloro-2-hydroxypropylamino)-phenyl)-morpholin-3-one with benzyl bromide or benzyl chloride optionally, in the presence of a suitable base to give (R)-4-(4-(N-benzyl-(3-chloro-2-hydroxypropyl)amino)phenyl)-morpholin-3-one (Ia); converting (Ia) to (S)-4-(4-(N-benzyl-(3-amino-2-hydroxypropyl)amino)phenyl)-morpholin-3-one phosphate (Ib) which may optionally involve isolation of (R)-4-(4-(N-benzyl-(3-azido-2-hydroxypropyl)amino)-phenyl)-morpholin-3-one (Ic); reacting (Ib) with 5-chlorothiophene-2-carbonyl chloride (Id) in the presence of a suitable base to give 5-chloro-thiophene-2-carboxylic acid ((S)-3-(benzyl-(4-(3-oxo-morpholin-4-yl)-phenyl)-amino)-2-hydroxy-propyl)-amide (II); and deprotecting and cyclizing (II) to provide (I);    (2) protecting group containing 4-(4-(2-hydroxy-ethylamino)-phenyl)-morpholin-3-one (VI), protecting group containing 4-(4-((S)-3-amino-2-hydroxy-propylamino)-phenyl)-morpholin-3-one (VII), protecting group containing 4-(4-((R)-3,3,3-triamino-2-hydroxy-propylamino)-phenyl)-morpholin-3-one (VIIA) or protecting group containing 5-chloro-thiophene-2-carboxylic acid((R)-2-hydroxy-3-(4-(3-oxo-morpholin-4-yl)-phenylamino)-propyl)-amide (IX); and    (3) (R)-4-(4-(N-benzyl-(3-chloro-2-hydroxypropyl)amino)phenyl)-morpholin-3-one (Ia), (S)-4-(4-(N-benzyl-(3-amino-2-hydroxypropyl)amino)phenyl)-morpholin-3-one phosphate (Ib), (R)-4-(4-(N-benzyl-(3-azido-2-hydroxypropyl)amino)-phenyl)-morpholin-3-one (Ic), 5-chloro-thiophene-2-carboxylic acid ((S)-3-(benzyl-(4-(3-oxo-morpholin-4-yl)-phenyl)-amino)-2-hydroxy-propyl)-amide (II), or 4-(4-(((S)-3-Amino-2-hydroxy-propyl)-benzyl-amino)-phenyl)-morpholin-3-one.